Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs dexmedetomidine for postoperative delirium in elderly joint replacement
ChiCTR2300078080Phase 4Recruiting
- Sponsor
- Zhuji People's Hospital of Zhejiang Province
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam and dexmedetomidine in postoperative delirium (POD) (3 arms), sponsored by Zhuji People's Hospital of Zhejiang Province. Primary endpoint: Postoperative delirium. Started Nov 2023; status: recruiting.
02
Drugs
remimazolamdexmedetomidine
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on ChiCTR2300078080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078080.